Omeros | OMER - Interest Expense On Debt


Omeros reported $4.05M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Adma Biologics USD 2.1M 474K Mar/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Cytokinetics USD 34.83M 1.5M Jun/2026
Gilead Sciences USD 247M 7M Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 197K 222K Dec/2025
Insmed USD 18.84M 1.24M Jun/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.62M 77K Jun/2026
Pfizer USD 667M 4M Jun/2026
Rockwell Medical USD 232K 199K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
United Therapeutics USD 2.9M 200K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025